Overview
SVRA market data
Price History
SVRA price chart · 1M
- O
- 5.59
- H
- 5.68
- L
- 5.52
- C
- 5.62
- Vol
- 101,097.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $5.59
- Previous Close
- $5.60
- Day High
- $5.68
- Day Low
- $5.52
- 52 Week High
- $6.48
- 52 Week Low
- $4.70
- 7 Day Return
- +0.36%
- 30 Day Return
- +3.50%
- 90 Day Return
- +10.20%
- 1 Year Return
- +6.54%
- Daily Notional Volume
- $568.2K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.48 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.19 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -4,253.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.08 – $7.01 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.1B · P/B 6.04 · P/S 4,168.47.
Company News
Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS CongressBenzinga · Aug 24, 2026, 8:08 PM
Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041Benzinga · Aug 11, 2026, 9:01 PM
Savara Q2 EPS $(0.16) Misses $(0.14) EstimateBenzinga · Aug 11, 2026, 8:37 PM
Savara Announces European And Australian Patents Granted Covering MOLBREEVI Liquid Formulation, Securing Protection Through March 2041Benzinga · Jul 30, 2026, 12:11 PM
Savara Announces Chief Financial and Administrative Officer TransitionBenzinga · Jun 8, 2026, 9:15 PM
8-K filing — Savara Inc (SVRA)SEC EDGAR · Jun 8, 2026, 8:15 PM
Savara Chief Financial And Administrative Officer Dave Lowrance Stepping Down, Effective July 15; COO Robert Lutz To Assume Additional Role Of CFOBenzinga · Jun 8, 2026, 8:15 PM